Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers
Sponsor: Hanmi Pharmaceutical Company Limited
Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.
Official title: An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Subjects
Key Details
Gender
All
Age Range
19 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12-19
Completion Date
2026-04-10
Last Updated
2025-12-22
Healthy Volunteers
Yes
Conditions
Interventions
HIP2503
Take 1 orally disintegrating tablet once per period
HCP1306
Take 1 tablet once per period
Locations (1)
H plus Yangji Hospital
Seoul, Gwanak-gu, South Korea